Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...